- Home
- KFS vs MGNX Comparison
KFS vs MGNX Comparison
Compare KFS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- MGNX
- Stock Information
- Founded
- KFS 1989
- MGNX 2000
- Country
- KFS United States
- MGNX United States
- Employees
- KFS N/A
- MGNX N/A
- Industry
- KFS Property-Casualty Insurers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- MGNX Health Care
- Exchange
- KFS Nasdaq
- MGNX Nasdaq
- Market Cap
- KFS 234.2M
- MGNX 257.3M
- IPO Year
- KFS 1996
- MGNX 2013
- Fundamental
- Price
- KFS $8.16
- MGNX $3.00
- Analyst Decision
- KFS
- MGNX Hold
- Analyst Count
- KFS 0
- MGNX 10
- Target Price
- KFS N/A
- MGNX $7.17
- AVG Volume (30 Days)
- KFS 59.7K
- MGNX 496.5K
- Earning Date
- KFS 03-04-2025
- MGNX 03-06-2025
- Dividend Yield
- KFS N/A
- MGNX N/A
- EPS Growth
- KFS N/A
- MGNX N/A
- EPS
- KFS N/A
- MGNX N/A
- Revenue
- KFS $108,627,000.00
- MGNX $141,329,000.00
- Revenue This Year
- KFS N/A
- MGNX $174.73
- Revenue Next Year
- KFS N/A
- MGNX N/A
- P/E Ratio
- KFS N/A
- MGNX N/A
- Revenue Growth
- KFS 2.02
- MGNX 16.68
- 52 Week Low
- KFS $7.60
- MGNX $2.95
- 52 Week High
- KFS $9.58
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- KFS 43.16
- MGNX 37.54
- Support Level
- KFS $7.74
- MGNX $3.00
- Resistance Level
- KFS $8.38
- MGNX $3.22
- Average True Range (ATR)
- KFS 0.18
- MGNX 0.17
- MACD
- KFS 0.02
- MGNX -0.02
- Stochastic Oscillator
- KFS 51.22
- MGNX 7.69
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).